来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

已收盘 07-31 16:08:41

6.050

+0.650

+12.04%

最高6.050	最低5.480	成交量170.17万
今开5.480	昨收5.400	日振幅10.56%
总市值27.16亿	流通市值27.16亿	总股本4.49亿
成交额998.82万	换手率0.38%	流通股本4.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":6.05,"timestamp":1785485321004,"preClose":5.4,"halted":0,"volume":1701652,"delay":0,"changeRate":0.12037037037037027,"floatShares":449000000,"shares":449000000,"eps":-0.59,"marketStatus":"已收盘","change":0.65,"latestTime":"07-31 16:08:41","open":5.48,"high":6.05,"low":5.48,"amount":9988229,"amplitude":0.105556,"askPrice":6.05,"askSize":12500,"bidPrice":6.03,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":-0.565,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785720600000},"marketStatusCode":5,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":5.4,"openAndCloseTimeList":[[1785461400000,1785470400000],[1785474000000,1785484800000]],"volumeRatio":1.142892,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"1191154605","title":"来凯医药-B于7月15日回购3.90万股，涉资约28.81万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191154605","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191154605?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:50","pubTimestamp":1784112649,"startTime":"0","endTime":"0","summary":"来凯医药-B（股票代码：02105）于2026年7月15日发布翌日披露报表，披露当日通过香港联交所场内回购普通股3.90万股，约占已发行股本0.0087%。回购价格介乎每股7.16港元至7.48港元，总成交金额约28.81万港元。\n回购完成后，公司已发行股本及库藏股数分别为449,331,350股及0股。根据2026年6月5日通过的回购授权，本次回购后公司已累计回购股份总数为219,000股，占授权通过当日已发行股本约0.0487%。公司确认，此次回购已遵守香港联交所相关上市规则及相关法规。\n公告由公司秘书柯晨煜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B于7月15日回购3.90万股，涉资约28.81万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131910117","title":"来凯医药-B7月14日回购4万股，涉资约27.67万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131910117","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131910117?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:36","pubTimestamp":1784028976,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年7月14日发布公告。根据翌日披露报表，来凯医药-B于当日于香港联交所场内回购普通股股份4万股，每股回购最高价为每股7.01港元，最低价为每股6.70港元，合计耗资约27.67万港元。回购完成后，公司已发行股本总数维持在449,331,350股，且无库存股份。公司于2026年6月5日获得最高回购股份数额为44,933,135股的授权，截至目前，已合计回购股份180,000股，占当日已发行股本约0.0401%。公司确认本次回购遵循相关上市规则及相关法例。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B7月14日回购4万股，涉资约27.67万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651170414","title":"来凯医药-B(02105)7月14日斥资27.7万港元回购4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170414","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651170414?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:26","pubTimestamp":1784028378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，于2026年7月14日斥资27.7万港元回购4万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197051668","title":"来凯医药-B于7月13日回购4万股，耗资约28.26万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197051668","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197051668?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:41","pubTimestamp":1783939318,"startTime":"0","endTime":"0","summary":"来凯医药有限公司2026年7月13日发布翌日披露报表。公告显示，公司于当日于香港联交所场内回购普通股4万股，占其已发行股本的约0.0089%。回购价格介乎每股港币6.78元至7.45元，累计支付对价约28.26万港元。此次回购股份尚未注销，截至2026年7月13日，公司已发行股份总数为449,331,350股，库藏股为0股。截至目前，在香港联交所及其他证券交易所已累计购回140,000股，占购回授权通过当日公司已发行股份数目的约0.0312%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B于7月13日回购4万股，耗资约28.26万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651134791","title":"来凯医药-B(02105)7月13日斥资28.26万港元回购4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651134791","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651134791?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:36","pubTimestamp":1783939014,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，于2026年7月13日该公司斥资28.26万港元回购4万股，回购价格为每股6.78-7.45港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B(02105)7月13日斥资28.26万港元回购4万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126976780","title":"来凯医药-B7月10日回购5万股股份，耗资约37.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126976780","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126976780?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:32","pubTimestamp":1783683143,"startTime":"0","endTime":"0","summary":"2026年7月10日，来凯医药有限公司发布翌日披露报表，公告公司于2026年7月10日在香港联交所场内回购普通股5万股。该部分股份占公司已发行股本约0.0111%，每股回购价格介乎港币7.39元至7.71元，平均回购价约港币7.5379元，合计涉资约37.69万港元。根据公告，回购股份暂未注销，公司已发行股本仍为449,331,350股，库藏股结存为0股。此前，公司于2026年6月5日通过购回授权，可回购股份总数为44,933,135股。公司确认本次回购行为遵守香港联交所主板上市规则及相关法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"来凯医药-B7月10日回购5万股股份，耗资约37.69万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650822941","title":"来凯医药-B(02105)7月10日斥资37.7万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650822941","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650822941?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:29","pubTimestamp":1783682998,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，于2026年7月10日斥资37.7万港元回购5万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115865759","title":"来凯医药-B：2026年7月9日回购5万股，耗资约35.51万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115865759","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115865759?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:51","pubTimestamp":1783594272,"startTime":"0","endTime":"0","summary":"来凯医药-B（02105）于2026年7月9日发布公告，披露当日于香港联交所场内回购股份5万股，占已发行股本约0.0111%。本次回购价格区间介乎每股6.98港元至7.37港元，合计耗资约35.51万港元。\n回购完成后，公司已发行股本仍为449,331,350股，无库藏股。此前购回授权于2026年6月5日获得通过，可回购总额为44,933,135股。公司确认已遵守香港联交所上市规则及相关法律法规。\n本次公告由公司秘书柯晨煜签署，公告日期为2026年7月9日。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B：2026年7月9日回购5万股，耗资约35.51万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650925269","title":"来凯医药-B(02105)7月9日斥资35.51万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650925269","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650925269?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:50","pubTimestamp":1783594244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，该公司于2026年7月9日斥资35.51万港元回购5万股股份，每股回购价格为6.98-7.37港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175908037","title":"来凯医药-B6月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1175908037","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175908037?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:12","pubTimestamp":1783069928,"startTime":"0","endTime":"0","summary":"来凱醫藥有限公司2026年6月股份变动月报表于2026年7月3日发布，报告期截至2026年6月30日。公告显示，公司法定/注册股本均未发生变化，截至报告期末，法定/注册股本总额为50,000美元，股本数量维持5,000,000,000股，面值为每股0.00001美元。在已发行股份方面，本月未有新增发行或股份变动。公司“2024年股份奖励计划”在报告期内亦无新股或库存股份变动。本月内，公司未进行任何股份购回及注销，股本总数相较上月保持不变。本公告由公司秘书柯晨煜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648728665","title":"港股异动 | 来凯医药-B(02105.HK)涨超7% 拟回购股份及高管拟增持股份 涉资最多5600万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648728665","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648728665?lang=zh_cn&edition=full","pubTime":"2026-07-02 14:56","pubTimestamp":1782975368,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648527295","title":"来凯医药-B(02105.HK)启动场内回购及管理层拟同步增持，合计最高斥资5600万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2648527295","media":"中金财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648527295?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:27","pubTimestamp":1782952024,"startTime":"0","endTime":"0","summary":"格隆汇7月2日丨来凯医药-B(02105.HK)发布公告，为彰显对公司业务前景的信心，并为股东创造价值，董事会于2026年7月1日批准，根据回购授权，在公开市场上购回股份。与此同时，董事会获悉，公司董事会主席吕向阳连同公司若干高级管理层成员，拟透过在公开市场上购买公司股份，以增持其于公司的股权。场内股份回购计划将以公司现有的可用现金资源拨付。公司其后将购回的股份注销。高级管理层增持股份计划将以其个人财务资源拨付。\r\n\r\n　　上述同步行动反映董事会及管理层对公司业务前景及未来发展充满信心，并将有利于公司及为股东创造价值。公司进行场内股份回购及高级管理层增持股份的合计金额最多为港币5600万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260702/32296702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377991","title":"来凯医药-B(02105)：柯晨煜担任公司秘书的资格获联交所确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377991","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647377991?lang=zh_cn&edition=full","pubTime":"2026-06-29 22:00","pubTimestamp":1782741658,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，联交所已确认柯晨煜先生符合上市规则第3.28条及第8.17条下担任本公司公司秘书的资格。本公司其中一名联席公司秘书何咏雅女士已提呈辞任本公司联席公司秘书及上市规则下的本公司授权代表，自2026年6月29日起生效。同时，何女士根据香港法例第622章《公司条例》第16部作为本公司授权代表，代本公司于香港接收法律程序文件及通知的持续角色维持不变。何女士辞任联席公司秘书后，柯先生将继续留任，并担任本公司的唯一公司秘书。柯先生亦已获委任为上市规则第3.05条下的本公司授权代表，自2026年6月29日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647328063","title":"格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓！","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647328063?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:08","pubTimestamp":1782709733,"startTime":"0","endTime":"0","summary":"本次评选共设有14个奖项","market":"sh","thumbnail":"https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5373783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02687","06963","01024","01952","01021","09992","02273","01768","06668","06979","02555","01384","02105","002352","01833","09959","02661","02643","07688","02590","300760","00917","01951","00780","03692","002714","09878","02526","02170","300364","02553","01497","03690","02511","001248","000338","00600","002594","02121","02279","02408","02718","002600","09880","000039","002779","000951","09678","01519","02729"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647340125","title":"港股异动 | 来凯医药-B(02105.HK)午前涨近15% 有关LAE118独家许可协议取得新进展 已收到Vasque Bio首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2647340125","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647340125?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:53","pubTimestamp":1782705189,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647419693","title":"替尔泊肽借力来凯医药-B(02105)LAE102联用，推动增肌减脂“中国方案”创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2647419693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647419693?lang=zh_cn&edition=full","pubTime":"2026-06-29 08:32","pubTimestamp":1782693155,"startTime":"0","endTime":"0","summary":"近年来，“增肌减脂”概念逐渐成为千亿减重市场新热门。而在“增肌减脂”方向，来凯医药-B自主研发的LAE102与礼来Bimagrumab是这一赛道的先行者。LAE102是全球范围内除了Bimagrumab之外，为数不多的已经进入临床试验阶段的靶向ActRII的在研品种。本次IIT通过LAE102与替尔泊肽联合使用，有望探索新一代联合疗法使肥胖患者获得更有效的长期获益，在“增肌减脂”这个巨大、潜在的未满足需求上推动“中国方案”的持续创新。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645868446","title":"来凯医药(2105.HK)PI3Kα抑制剂授权出海 已收到合作伙伴Vasque Bio首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2645868446","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645868446?lang=zh_cn&edition=full","pubTime":"2026-06-24 08:57","pubTimestamp":1782262621,"startTime":"0","endTime":"0","summary":"2026年6月24日——来凯医药宣布：来凯与Vasque Bio 6月9日签订的有关LAE118独家许可协议取得新进展：集团已根据许可协议，收到了Vasque Bio的首付款，包括1000万美元现金以及一项权益——即无需额外对价的情况下，有权获得Vasque Bio 已发行普通股最多达高双位数百分比的股权，或替代该等普通股的现金付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260624/32287844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644719112","title":"【券商聚焦】国泰海通维持来凯医药-B(02105)“增持”评级 看好与Vasque签订的LAE118独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2644719112","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644719112?lang=zh_cn&edition=full","pubTime":"2026-06-17 15:55","pubTimestamp":1781682934,"startTime":"0","endTime":"0","summary":"维持“增持”评级，给予目标价14.15港元。研报核心关注点在于来凯医药与Vasque Bio签订的LAE118独家许可协议。根据协议，来凯医药有权获得1000万美元首付款、Vasque Bio最高达高双位数百分比的普通股股权、总额最高达5.17亿美元的里程碑付款，以及许可区域内净销售额个位数至双位数百分比的梯度销售分成。若Vasque Bio达成符合特定条件的战略合作或收购交易，来凯医药还可获得最高达该交易价值50%的额外付款。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984001","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105","02611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642072259","title":"港股异动 | 来凯医药-B(02105)涨超5% 近日就LAE118与Vasque Bio签订全球独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2642072259","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642072259?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:37","pubTimestamp":1781235478,"startTime":"0","endTime":"0","summary":"消息面上，来凯医药-B发布公告，于2026年6月9日，本集团与Vasque Bio,Inc.签订了一项独家许可协议。作为回报，本集团有权获得一笔不可退还且不可抵扣的首付现金款项1000万美元，以及在无需额外对价的情况下，有权获得Vasque Bio已发行普通股最多达高双位数百分比的股权，或替代该等普通股的现金付款。如Vasque Bio达成符合特定条件的合格战略合作或收购交易，本集团将有权获得额外付款，金额最高可达该战略交易价值的50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","02105","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642047201","title":"5.27亿美元！来凯医药（02105）黄金靶点，站上NewCo 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2642047201","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642047201?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:37","pubTimestamp":1781138277,"startTime":"0","endTime":"0","summary":"康诺亚CM3362024年以NewCo交易出海，首付款仅1600万美元，但NewCo公司今年被吉利德以21.75亿美元收购，康诺亚斩获2.57亿美元首付款。来凯LAE118出海首付款为1000万美元，但Vasque Bio后续若被收购，来凯分成比例最高达50%。作为经典的黄金靶点，PI3Kα仍在赶赴大药之旅。诺华Alpelisib自2019年获批上市以来，销售峰值止步于5亿美元级别。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IAU","DUST","FGDL","SHNY","OUNZ","RING","BAR","GOAU","1OZmain","CEF","BEGS","MGCmain","USG","GDXY","GBUG","GCmain","AAAU","DGP","GDXD","PICK","UYM","XME","GDX","GOLY","GDXJ","SGOL","UGL","IAUM","02105","JDST","PALL","GLL","DULL","SGUmain","NUGT","DZZ","159831","BTGD","GLD","GLTR","SGDM","QOmain","JNUG","159934","SGCmain","GDXU","IAUI","GLDM","PHYS","DBC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":-0.1988},{"period":"1month","weight":-0.1964},{"period":"3month","weight":-0.6189},{"period":"6month","weight":-0.6058},{"period":"1year","weight":-0.7182},{"period":"ytd","weight":-0.6021}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":0.1301},{"period":"3month","weight":0.0032},{"period":"6month","weight":-0.0558},{"period":"1year","weight":0.0271},{"period":"ytd","weight":0.0089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.264392},{"month":2,"riseRate":0.666667,"avgChangeRate":0.234103},{"month":3,"riseRate":0.666667,"avgChangeRate":0.090739},{"month":4,"riseRate":0.333333,"avgChangeRate":0.001974},{"month":5,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":6,"riseRate":0,"avgChangeRate":-0.226423},{"month":7,"riseRate":0.25,"avgChangeRate":-0.096698},{"month":8,"riseRate":0.666667,"avgChangeRate":0.069227},{"month":9,"riseRate":0.666667,"avgChangeRate":0.04052},{"month":10,"riseRate":0.666667,"avgChangeRate":0.10793},{"month":11,"riseRate":1,"avgChangeRate":0.401946},{"month":12,"riseRate":0,"avgChangeRate":-0.176326}],"exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}